Telix Pharmaceuticals Lim... (TLX)
| Bid | 13.61 |
| Market Cap | 4.61B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | 0.09 |
| PE Ratio (ttm) | 153.11 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 14.21 |
| Volume | 111,291 |
| Avg. Volume (20D) | 32,170 |
| Open | 14.90 |
| Previous Close | 16.15 |
| Day's Range | 13.75 - 15.05 |
| 52-Week Range | 13.75 - 30.36 |
| Beta | 2.49 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibo...
Analyst Forecast
According to 1 analyst ratings, the average rating for TLX stock is "Strong Buy." The 12-month stock price forecast is $22, which is an increase of 59.65% from the latest price.
Stock Forecasts
2 weeks ago · investopedia.com
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening AgentShares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.
